PDS Biotechnology

HC Wainwright reiterated PDS Biotechnology's 'buy' rating with a $21.00 target. Alliance Global Partners upgraded to 'strong-buy'. MarketBeat reports a 'Moderate Buy' average rating and $14.25 consensus target. PDS Biotechnology shares traded down $0.04 to $3.08 on Thursday, with a 52-week range of $2.53-$6.85. The company reported a $0.23 EPS for the quarter, beating estimates by $0.08.

The article discusses the use of SSR (Server-Side Rendering) for improving web performance and user experience, focusing on the implementation of SSR in modern web applications.

PDS Biotechnology (PDSB) to discuss PDS01ADC trial design for recurrent prostate cancer treatment at the 12th Annual Meeting of the International Cytokine & Interferon Society in Seoul.

Dynavax Technologies and PDS Biotechnology are compared based on analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings, and risk. PDS Biotechnology has a higher consensus rating and potential upside, while Dynavax Technologies has higher revenue and earnings. Dynavax Technologies outperforms PDS Biotechnology on 8 of 14 factors.

PDS Biotechnology and InflaRx are small-cap medical companies. PDS has higher earnings but lower revenue than InflaRx, trading at a lower price-to-earnings ratio. Analysts favor InflaRx due to its stronger consensus rating and higher potential upside. InflaRx also has higher institutional ownership and lower volatility compared to PDS Biotechnology.

Noble Financial's Robert LeBoyer reiterated a Buy rating on Tonix Pharma (TNXP) on Oct 11, setting a $1.50 price target. Tonix shares closed at $0.15. LeBoyer, with an average return of -9.4% and a 27.97% success rate, covers Healthcare stocks. Tonix has a Moderate Buy consensus with a $6.25 price target. The company, founded in 2007, focuses on developing treatments for psychiatric, pain, and addiction conditions.

H.C. Wainwright reaffirms Buy rating for PDS Biotechnology Corp following IMMUNOCERV trial update, showing 84.4% overall survival rate at 36 months, increasing to 100% with full treatment doses. The trial also reported 74.9% progression-free survival rate, with 88% complete metabolic response. PDS Biotech plans to enroll 400-450 patients in upcoming Versamune HPV trials, supported by FDA. Despite not yet profitable, PDSB shows strong market performance with 31.31% return last week and 36.09% last month.

H.C. Wainwright & Co. analyst Dr. Joseph Pantginis maintains a Buy rating on PDS Biotechnology Corp. (PDSB:NASDAQ) with a price target of US$21.00, based on promising results from the IMMUNOCERV trial showing enhanced response rates and survival in advanced cervical cancer patients treated with PDS0101 in combination with standard chemoradiation.

HC Wainwright reaffirms PDS Biotechnology's "buy" rating with a $21.00 price target, indicating a potential 486.59% upside. Other analysts also maintain positive ratings, with a consensus "Moderate Buy" and an average target price of $14.25. PDS Biotechnology's stock fell 1.9% to $3.58 on Wednesday, with a market cap of $131.31 million.